London · Delayed Price · Currency is GBP · Price in USD Integrated Diagnostics Holdings Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw 37% revenue growth, margin expansion, and strong performance in Egypt, Nigeria, and Saudi Arabia. 2026 guidance targets 25% sales growth, 200 new branches, and continued investment, with risks from regional geopolitics and currency volatility.
-
Strong nine-month 2025 results featured 41% revenue growth, margin expansion, and robust performance in Egypt, Jordan, Nigeria, and Saudi Arabia. Guidance for 2025 remains above 35% revenue growth and 30%+ EBITDA margin, with continued network expansion and cost discipline.
-
Strong H1 2025 results featured 42% revenue growth, margin expansion, and robust performance across Egypt, Saudi Arabia, Nigeria, and Jordan. Strategic investments, digitalization, and a resumed dividend underpin positive full-year guidance and continued market leadership.
-
Q1 2025 saw 35% revenue growth and margin expansion, driven by higher average revenue per test and effective cost control. Egypt, Jordan, and Nigeria delivered strong results, while Saudi Arabia ramp-up continues. Full-year revenue growth is guided at 30%+ with EBITDA margin above 30%.
Fiscal Year 2024
-
Record 2024 results with 39% revenue growth and margin improvements despite macro challenges. Expansion in Saudi and radiology, strong cash reserves, and a 33% revenue growth outlook for 2025, with dividend payout deferred to support growth and manage risks.
-
Revenue grew 34% year-on-year to EGP 4.1 billion, with strong margin improvements and net profit up 87%. Egypt led growth, while Nigeria and Saudi Arabia showed progress despite currency and regulatory challenges. Full-year guidance reaffirmed at 30% revenue growth and 30% EBITDA margin.
-
Revenue grew 33% year-over-year to EGP 2.5 billion, with strong margin expansion and net profit up 127%, driven by Egypt’s robust performance and cost controls. Guidance for 2024 targets 30% revenue growth and 30% EBITDA margin, with continued focus on operational efficiency and selective expansion.
-
Q1 2024 saw 28% revenue growth to EGP 1.2bn, with Egypt driving performance and margins improving across all levels. Guidance for 2024 is 30% revenue growth and a 30% EBITDA margin, excluding Saudi Arabia and non-recurring items.